Publication details
Macugen v léčbě vlhké formy věkem podmíněné makulární degenerace
| Title in English | Macugen in treatment of wet form of age related macular degeneration |
|---|---|
| Authors | |
| Year of publication | 2009 |
| MU Faculty or unit | |
| Citation | |
| Description | Discovery of endothelial growth factor antagonists radical affected therapy of the wet form of age related macular degeneration. The first approved antagonist is pegaptanib (Macugen) that selectively blocked VEGF-165 isoform. This isoform is responsible for initialising of pathological neovascularization. |